ALT Logo

Altimmune, Inc. (ALT) 

NASDAQ$5.2
Market Cap
$400.47M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
441 of 925
Rank in Industry
261 of 528

ALT Insider Trading Activity

ALT Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$000
Sells
$110,5471100

Related Transactions

Drutz Daviddirector0$01$110,547$-110,547

About Altimmune, Inc.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known â€¦

Insider Activity of Altimmune, Inc.

Over the last 12 months, insiders at Altimmune, Inc. have bought $0 and sold $110,547 worth of Altimmune, Inc. stock.

On average, over the past 5 years, insiders at Altimmune, Inc. have bought $7.62M and sold $897,547 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 300 shares for transaction amount of $863 was made by Drutz David (director) on 2023‑08‑15.

List of Insider Buy and Sell Transactions, Altimmune, Inc.

2024-08-19SaleDrutz Daviddirector
16,011
0.0206%
$6.90$110,547-8.49%
2023-08-15PurchaseDrutz Daviddirector
300
0.0006%
$2.88$863+145.20%
2023-03-24PurchaseEisenstadt Richard IChief Financial Officer
10,000
0.0213%
$4.31$43,140-5.32%
2023-03-23PurchaseHarris Matthew ScottChief Medical Officer
10,000
0.0215%
$4.22$42,200-2.39%
2023-03-23PurchaseDrutz Daviddirector
9,000
0.0195%
$4.27$38,430-2.39%
2022-12-22SalePisano Waynedirector
20,000
0.0383%
$15.01$300,268-73.88%
2022-08-30SaleGarg Vipin KPresident and CEO
20,000
0.0429%
$20.02$400,322-47.31%
2022-08-12SaleGarg Vipin KPresident and CEO
15,000
0.0264%
$15.06$225,890-39.92%
2022-08-12SaleGILL JOHNdirector
2,714
0.0048%
$15.00$40,710-39.92%
2022-07-01SaleRoberts M ScotChief Scientific Officer
10,182
0.022%
$12.00$122,184+0.62%
2022-06-29SaleRoberts M ScotChief Scientific Officer
5,462
0.0117%
$12.00$65,546-3.74%
2022-06-27SaleRoberts M ScotChief Scientific Officer
37,352
0.0803%
$12.00$448,254-3.40%
2022-06-27SaleJorkasky Diane
17,610
0.0371%
$11.75$206,944-3.40%
2022-06-15PurchaseDrutz David
1,000
0.002%
$8.00$8,000+36.66%
2022-05-24PurchaseDrutz David
1,200
0.0024%
$4.50$5,400+140.89%
2022-02-28SaleHarris Matthew ScottChief Medical Officer
30,000
0.0692%
$7.52$225,600+52.50%
2021-03-01SaleHodges Philipdirector
6,000
0.0151%
$16.08$96,480-28.09%
2020-12-10PurchaseSchafer Klausdirector
2,000
0.0076%
$11.99$23,980+5.50%
2020-12-01SaleHodges Philipdirector
1,227
0.0047%
$13.54$16,614-6.30%
2020-11-30SaleHodges Philipdirector
2,500
0.0096%
$12.00$30,000+6.26%
Total: 148
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Drutz Daviddirector
41958
0.0545%
$218,181.6061+43.65%
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.10 percent owner
6626403
8.6042%
$34.46M13
EVNIN LUKE10 percent owner
6347614
8.2422%
$33.01M20
MPM BIOVENTURES III LLC10 percent owner
6347614
8.2422%
$33.01M20
Venrock Healthcare Capital Partners III, L.P.10 percent owner
4500000
5.8431%
$23.4M40+64.5%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$84,871,118
57
17.71%
$406.62M
Altimmune, Inc.
(ALT)
$24,384,691
42
-30.27%
$400.47M
$26,923,982
20
-17.22%
$415.61M
$73,222,926
18
60.19%
$406.77M
$276,750,010
16
-7.95%
$381.52M

ALT Institutional Investors: Active Positions

Increased Positions102+58.29%5M+13.58%
Decreased Positions69-39.43%4M-10.63%
New Positions38New870,626New
Sold Out Positions24Sold Out1MSold Out
Total Postitions208+18.86%41M+2.95%

ALT Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Blackrock, Inc.$40,959.008%6.16M+693,211+12.68%2024-12-31
Ameriprise Financial Inc$34,945.006.83%5.25M+1M+35.57%2024-12-31
Vanguard Group Inc$29,470.005.76%4.43M-552,246-11.08%2024-12-31
State Street Corp$23,076.004.51%3.47M+56,190+1.65%2024-12-31
Tang Capital Management Llc$18,288.003.57%2.75M00%2024-12-31
Geode Capital Management, Llc$11,029.002.15%1.66M-9,498-0.57%2024-12-31
Knoll Capital Management, Llc$7,458.001.46%1.12M00%2024-12-31
Bellevue Group Ag$6,287.001.23%945,446+81,786+9.47%2024-12-31
Morgan Stanley$6,130.001.2%921,822-373,763-28.85%2024-12-31
Ubs Group Ag$4,785.000.93%719,555+437,100+154.75%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
1.9SellsBuysStrong BuyBuyHoldSellStrong SellALTHighAverageLowSeries 4